PDF(Pubmed)
Abstract：
UNASSIGNED: The DAPA-CKD study showed a protective effect of dapagliflozin on kidney function in chronic kidney disease (CKD) patients with and without diabetes mellitus. Although dapagliflozin is expected to be effective also in CKD patients with autosomal dominant polycystic kidney disease (ADPKD), its efficacy and safety in this population remain unknown because ADPKD was an exclusion criterion in the DAPA-CKD study. Therefore, we evaluated the effects of dapagliflozin in CKD patients with ADPKD.
UNASSIGNED: We performed a retrospective observational study of seven patients with ADPKD treated with dapagliflozin at Toranomon Hospital, Tokyo, Japan. We analyzed changes in estimated glomerular filtration rate (eGFR) slope and annual height-corrected total kidney volume before and after starting dapagliflozin treatment.
UNASSIGNED: The median observation period after starting dapagliflozin was 20 months. Four patients received concomitant tolvaptan. The eGFR slope before and after initiation of dapagliflozin could be calculated in six patients and improved in all of them except the one who did not receive a renin-angiotensin system (RAS) inhibitor. Annual height-corrected total kidney volume increased in all patients. Concurrent tolvaptan treatment had no effect.
UNASSIGNED: In CKD patients with ADPKD, dapagliflozin may increase kidney volume but may have a protective effect on kidney function when used concomitantly with RAS inhibitors.
UNASSIGNED: We performed a retrospective observational study of seven patients with ADPKD treated with dapagliflozin at Toranomon Hospital, Tokyo, Japan. We analyzed changes in estimated glomerular filtration rate (eGFR) slope and annual height-corrected total kidney volume before and after starting dapagliflozin treatment.
UNASSIGNED: The median observation period after starting dapagliflozin was 20 months. Four patients received concomitant tolvaptan. The eGFR slope before and after initiation of dapagliflozin could be calculated in six patients and improved in all of them except the one who did not receive a renin-angiotensin system (RAS) inhibitor. Annual height-corrected total kidney volume increased in all patients. Concurrent tolvaptan treatment had no effect.
UNASSIGNED: In CKD patients with ADPKD, dapagliflozin may increase kidney volume but may have a protective effect on kidney function when used concomitantly with RAS inhibitors.
摘要：
■DAPA-CKD研究表明，达格列净对患有和不患有糖尿病的慢性肾病（CKD）患者的肾功能具有保护作用。尽管达格列净预计在患有常染色体显性遗传性多囊肾病（ADPKD）的CKD患者中也有效，由于ADPKD是DAPA-CKD研究中的排除标准,因此其在该人群中的有效性和安全性仍然未知.因此,我们评估了达格列净对CKD伴ADPKD患者的疗效.
我们进行了一项回顾性观察研究，研究对象为7名在托罗门医院接受达帕格列净治疗的ADPKD患者，东京,日本。我们分析了在开始dapagliflozin治疗前后，估计的肾小球滤过率（eGFR）斜率和年度高度校正的总肾脏体积的变化。
■开始达格列净后的中位观察期为20个月。四名患者同时接受托伐普坦治疗。可以在6例患者中计算dapagliflozin开始之前和之后的eGFR斜率，并且除了未接受肾素-血管紧张素系统（RAS）抑制剂的患者外，所有患者均有所改善。所有患者的年身高校正总肾脏体积均增加。同时托伐普坦治疗没有效果。
■在患有ADPKD的CKD患者中，达格列净可增加肾脏体积,但与RAS抑制剂同时使用时可能对肾功能有保护作用.
我们进行了一项回顾性观察研究，研究对象为7名在托罗门医院接受达帕格列净治疗的ADPKD患者，东京,日本。我们分析了在开始dapagliflozin治疗前后，估计的肾小球滤过率（eGFR）斜率和年度高度校正的总肾脏体积的变化。
■开始达格列净后的中位观察期为20个月。四名患者同时接受托伐普坦治疗。可以在6例患者中计算dapagliflozin开始之前和之后的eGFR斜率，并且除了未接受肾素-血管紧张素系统（RAS）抑制剂的患者外，所有患者均有所改善。所有患者的年身高校正总肾脏体积均增加。同时托伐普坦治疗没有效果。
■在患有ADPKD的CKD患者中，达格列净可增加肾脏体积,但与RAS抑制剂同时使用时可能对肾功能有保护作用.
